Research Article| Volume 12, ISSUE 4, P711-721, December 1992

leukocyte-reduced blood components in transfusion medicine: Current Indications and Prospects for the Future

  • Ellen B. Klapper
    Address reprint requests to: Ellen B. Klapper, MD, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard—#4526, Los Angeles, CA 90048
    From the Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California
    Search for articles by this author
  • Dennis Goldfinger
    From the Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California

    University of California School of Medicine, Los Angeles, California
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.
      Transfusion medicine is a rapidly evolving specialty, and efforts are ongoing to improve the safety and quality of blood component therapy. Leukocytes are known to be the cause of numerous adverse effects of transfusion therapy, and their removal from red cells and platelet components may be desirable in a variety of clinical settings. The various complications of transfusion that can be attributed to contaminating leukocytes and the benefits of leukocyte depletion are addressed in this article. Laboratory as well as clinical data are summarized.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Andreu G.
        • Dewailly J.
        • Leberre C.
        • et al.
        Prevention of FILA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration.
        Blood. 1988; 72: 964-969
        • Blumberg N.
        • Heal J.M.
        Transfusion and recipient immune function.
        Arch Pathol Lab Med. 1989; 113: 246-253
        • Blumberg N.
        • Triulzi D.
        • Heal J.M.
        Transfusion-induced immunomodulation and its clinical consequences.
        Transfusion Med Rev. 1990; 4: 24-35
        • Bove J.R.
        Transfusion-transmitted diseases other than AIDS and hepatitis.
        Yale J Biol Med. 1990; 63: 347-351
        • Bowden R.A.
        • Slichter S.J.
        • Sayers M.H.
        • et al.
        Use of leukocyte-depleted platelets cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant.
        Blood. 1991; 78: 246-250
        • Brittingham T.E.
        • Chaplin Jr, H.
        Febrile transfusion reactions caused by sensitivity to donor leukocytes and platelets.
        JAMA. 1957; 165: 819-825
        • Bucholz D.H.
        • AuBuchon J.R.
        • Snyder E.
        • et al.
        Leukocyte depletion and bacterial proliferation in blood components [abstract].
        Transfusion. 1991; 31 (8S):63(S)
        • Bucholz D.H.
        • Snyder E.
        • AuBuchon J.P.
        • et al.
        Proliferation of Yersinia enterocolitica in leukodepleted and non-depleted red cells [abstract #5234].
        Transfusion. 1991; 31: 635
        • Capon S.
        • DePond W.D.
        • Tyan D.B.
        • et al.
        Transfusion-associated graft-versus-host disease in an immunocompetent patient.
        Ann Intern Med. 1991; 114: 1025-1026
        • DeGraan-Hentzen Y.C.E.
        • Gratama J.W.
        • Mudde G.C.
        • et al.
        Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products.
        Transfusion. 1989; 29: 757
        • Gilbert G.L.
        • Hayes K.
        • Hudson I.L.
        • et al.
        Prevention of transfusion acquired cytomeg-alovirus infection in infants by blood filtration to remove leukocytes: Neonatal cytomegalovirus Infection Study Group.
        Lancet. 1989; 1: 1228-1231
        • Goldfinger D.
        • Lowe C.
        Prevention of adverse reactions to blood transfusion by the administration of saline washed red blood cells.
        Transfusion. 1981; 21: 277-280
        • Janot C.
        • Briquel M.E.
        • Streiff F.
        Infectious complications due to transfusion acquired Yersinia enterocolitica [letter].
        Transfusion. 1989; 29: 372-373
        • Kruskall M.S.
        • Alper C.A.
        • Awdeh Z.
        • et al.
        HLA-homozygous donors and transfusion-associated graft-versus-host disease [letter].
        N Engl J Med. 1990; 322: 1005-1006
        • Luban N.L.C.
        • Williams A.E.
        • MacDonald M.G.
        • et al.
        Low incidence of acquired cytomegalovirus infection in neonates transfused with washed red blood cells.
        Am J Clin Pathol. 1987; 141: 416-419
        • Mangano M.M.
        • Chambers L.A.
        • Kruskall M.S.
        Limited efficacy of leuko-poor platelets for prevention of febrile transfusion reactions.
        Am J Clin Pathol. 1991; 95: 733-738
        • Meryman H.T.
        Transfusion induced alloimmunization and immunosuppression and the effects of leukocyte depletion.
        Transfusion Med Rev. 1989; 3: 180-193
        • Morrow J.F.
        • Braine H.G.
        • Kickler T.S.
        • et al.
        Septic reactions to platelet transfusions.
        JAMA. 1991; 266: 555-558
        • Murphy M.F.
        • Metcalfe P.
        • Thomas H.
        • et al.
        Use of leukocyte-poor blood components and HLA-matched platelet donors to prevent HLA alloimmunization.
        Br J Hematol. 1986; 62: 529-534
        • Opelz G.
        • Sengar D.P.S.
        • Mickey M.R.
        • et al.
        Effect of blood transfusions on subsequent kidney transplants.
        Transplant Proc. 1973; 5: 253-259
        • Opelz G.
        • Terasaki P.
        Dominant effect of transfusions on kidney graft survival.
        Transplantation. 1980; 29: 153-158
        • Perkins H.A.
        • Payne R.
        • Ferguson J.
        Non-hemolytic febrile transfusion reactions.
        Vox Sang. 1966; 11: 578-600
        • Reusser P.
        • Fisher L.D.
        • Buckner C.D.
        • et al.
        Cytomegalovirus infection after autologous bone marrow transplantation: Occurrence of cytomegalovirus disease and effect on engraftment.
        Blood. 1990; 75: 1888-1894
        • Saarinen U.M.
        • Kekomaki R.
        • Siimes M.A.
        • et al.
        Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components.
        Blood. 1990; 75: 512-517
        • Sachs D.H.
        Specific transplantation tolerance.
        N Engl J Med. 1991; 325: 1240-1241
        • Schiffer C.A.
        Prevention of alloimmunization against platelets.
        J Am Soc Hematol. 1991; 77: 1-4
        • Sniecinski I.
        • O’Donnell M.R.
        • Nowicki B.
        • et al.
        Prevention of refractoriness and HLA-alloimmunization using filtered blood products.
        Blood. 1988; 71: 1402-1407
        • Solis R.T.
        • Goldfinger D.
        • Gibbs M.B.
        • et al.
        Physical characteristics of microaggregates in stored blood.
        Transfusion. 1974; 14: 538-550
        • Tegtmeier G.E.
        Post-transfusion cytomegalovirus infections.
        Arch Pathol Lab Med. 1989; 113: 236-245
        • Tipple M.A.
        • Bland L.A.
        • Murphy J.J.
        • et al.
        Sepsis associated with transfusion of red cells contaminated with Yersinia enterocolitica.
        Transfusion. 1990; 30: 207-213
        • Van Marwijk Kooy M.
        • Van Prooijen H.
        • Moes M.
        • et al.
        Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective, randomized trial.
        Blood. 1991; 77: 201-205
        • Van Twuyver E.
        • Mooijaart R.J.D.
        • Ten Berge I.J.M.
        • et al.
        Pretransplantation blood transfusion revisited.
        N Engl J Med. 1991; 325: 1210-1213
        • Voogt P.J.
        • Van De Velde C.J.H.
        • Brand A.
        • et al.
        Perioperative blood transfusion and cancer prognosis.
        Cancer. 1987; 59: 836-843